Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin

Bone Marrow Transplantation

Volumn 35, Issue 5, 2005, Pages 515-519

  Wetzig, T ^a   Sticherling, M ^a   Simon, J C ^a   Hegenbart, U ^a   Niederwieser, D ^a   Al Ali, H K ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Graft versus host disease; Phototherapy; Stem cell transplantation; UVA1

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PSORALEN; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; ATOPIC DERMATITIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LICHENOID ERUPTION; MALE; PHOTOTHERAPY; PILOT STUDY; PRIORITY JOURNAL; PUVA; RELAPSE; SAFETY; SCLERODERMA; SKIN DISEASE; SKIN MANIFESTATION; STEM CELL TRANSPLANTATION; STEROID THERAPY; T LYMPHOCYTE; ULTRAVIOLET A RADIATION;

ACUTE DISEASE; ADULT; AGED; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LICHENOID ERUPTIONS; MALE; MIDDLE AGED; PHOTOTHERAPY; PILOT PROJECTS; SCLERODERMA, LOCALIZED; SKIN DISEASES; TREATMENT OUTCOME;

EID: 15544366129     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704804     Document Type: Article

References (29)

1. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
2. Beatty PG, Hanson JA, Longton GM et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443-447.
3. Ringden O, Backman L, Lonnqvist B et al. A randomized trial comparing use of cyclosporin and methtrexate for prophylaxis of graft-versus-host disease in bone marrow transplant recipients with hematological malignancies. Bone Marrow Transplant 1986; 1: 41-51.
4. Sullivan K, Agura E, Anasetti C. Chronic graft versus host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
5. Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host-disease after bone marrow transplant. Annu Rev Med 2003; 54: 29-52.
6. Simon JC, Pfleger D, Schopf E. Recent advances in phototherapy. Eur J Dermatol 2000; 10: 642-645.
7. Dawe RS, Ultraviolet A1 phototherapy. Topical review. Br J Dermatol 2003; 148: 626-637.
8. Grundmann-Kollmann M, Behrens S, Gruss C et al. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol 2000; 42: 134-136.
9. Staender H, Schiller M, Schwarz T. UVA1 therapy for sclerodermic graft-versus-host disease of the skin. J Am Acad Dermatol 2002; 46: 799-800.
10. Calzavara Pinton P, Porta F, Izzi T et al. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease. Haematologica 2003; 88: 1169-1175.
11. Glucksberg H, Storb R, Fever A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974; 18: 295-304.
12. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. N Engl J Med 1975; 292: 895-902.
13. Doney KC, Weiden PL, Storb R et al. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981; 11: 1-8.
14. Arai S, Vogelsang GB. Management of graft-versus-host disease. Blood Rev 2000; 14: 190-204.
15. Aubin F, Brion A, Deconinck E et al. Phototherapy in the treatment of cutaneous graft-versus-host disease. Our preliminary experience in resistant patients. Transplantation 1995; 59: 151-155.
16. Eppinger T, Ehninger G, Steinert M et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990; 50: 807-811.
17. Leiter U, Kaskel P, Kraehn G et al. Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease. Photodermatol Photoimmunol Photomed 2002; 18: 183-190.
18. Furlong T, Leisenring W, Storb R et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 206-212.
19. Wiesmann A, Weller A, Lischka G et al. Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study. Bone Marrow Transplant 1999; 23: 151-155.
20. Reinauer S, Lehmann P, Plewig G et al. Photochemotherapy (PUVA) of acute graft-versus-host disease. Hautarzt 1993; 44: 708-712.
21. Wetzig T, Al-Ali HK, Kirstner S et al. Primary PUVA phototherapy can be effective for acute graft-versus-host disease of the skin. Bone Marrow Transplant 2004; 33: 183 (Abstract).
22. Greinix HT, Volc-Platzer B, Kahls P et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000; 96: 2426-2431.
23. Greinix HT, Volc-Platzer B, Rabitsch W et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098-3104.
24. Morita A, Werfel T, Stege H et al. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med 1997; 186: 1763-1768.
25. Grewe M, Gyufko K, Schopf E et al. Lesional expression of interferon-ã in atopic eczema. Lancet 1994; 343: 25-26.
26. Krutmann J. Ultraviolet A radiation-induced immunomodulation: molecular and photobiological mechanisms. Eur J Dermatol 1998; 8 200-202.
27. Petersen MJ, Hansen C, Craig S. Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. J Invest Dermatol 1992; 99: 440-444.
28. van Kranen HJ, de Laat A, van de Ven J et al. Low incidence of p53 mutations in UVA (365-nm)-induced skin tumors in hairless mice. Cancer Res 1997; 57: 1238-1240.
29. Wallenfang K, Stadler R. Assoziation zwischen UVA1 bzw. Bade-PUVA-Bestrahlung und Melanomentwicklung? Hautarzt 2001; 52 705-707.